Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 08:30
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment

Overview:
Duchenne muscular dystrophy is a genetic disorder which causes progressive muscle degeneration and weakness, and it is one of the nine types of muscular dystrophy. Duchenne muscular dystrophy mostly affects males, but in rare cases occurs in females. Onset of the disease is generally 3 to 4 years of age and begins on hips, pelvic region, shoulders, and upper legs. Symptoms may include delayed or difficulty inability to stand, walk and difficulty in speaking.
Disease is diagnosed through the patient history, blood test for creatinine phosphokinase levels, molecular genetic testing, and muscle biopsy. There is no cure available for the disease till now. But the medications are available forrelieving the symptoms of the disease. Eteplirsen is used to treat the patients with specific gene mutation of gene that leads to DMD. Deflazacort, approved in 2017, becoming first corticosteroid to treat Duchenne muscular dystrophy.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/duchenne-muscular-dystrophydmd-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By formulation, Duchenne muscular dystrophy pipeline drugs are segmented into
• Oral
• Parenteral
• Others
By therapy, Duchenne muscular dystrophy pipeline drugs are segmented into
• Exon Skipping
• Gene Therapy
• Corticosteroids
• Others
By trial phase, Duchenne muscular dystrophy pipeline drugs are segmented into
• Phase I
• Phase II
• Phase III
• Phase IV
By company, Duchenne muscular dystrophy pipeline drugs are segmented into
• Pfizer Inc. (U.S.)
• ReveraGenBioPharma, Inc. (U.S.)
• Sarepta Therapeutics Inc. (U.S.)
• Daiichi Sankyo Company (Japan)
• BioMarin Pharmaceutical Inc. (U.S.)
• NS Pharma, Inc. (Japan)
• TAIHO PHARMACEUTICAL CO. (Japan)

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/duchenne-muscular-dystrophydmd-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu



Space Analysis:
Until the approval of exon skipping agent eteplirsen, carticostroids are the only potential treatment for the treatment of duchenne muscular atrophy, but with many side effects. Duchenne muscular dystrophy pipeline has the robust drug molecules and therapies such as gene therapy, exon skipping agents and also promising corticosteroids for the treatment. Furthermore, Catabasis Pharmaceuticals has been developing NF-kB protein inhibitor in phase-II development to treat duchenne muscular dystrophy. Moreover, there are numerous early stage development of drugs including, drugs which targets calcium regulation, fibrosis and oxidative stress.
• In November 2016, Wave Life Sciences Ltd. Initiated the Phase I clinical trial for WVE-210201 Duchenne muscular dystrophy patients amenable to exon 51 skipping.

Report Description:
Duchenne Muscular Dystrophy Pipeline Drugs Assessment report studies the various therapeutics under clinical development for XYX treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Duchenne muscular dystrophy pipeline drugsdevelopment. This report studies the dynamics of the Duchenne Muscular Dystrophy Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Duchenne muscular dystrophy pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/duchenne-muscular-dystrophydmd-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis onthe each drug candidates in the clinical trial phases

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/duchenne-muscular-dystrophydmd-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.